All webcasts
Revenue
$321.39M
-4.4% YoY
Diluted EPS
$0.70
-5.4% YoY
Gross margin
59.8%
+7.8 pp YoY
Net income
$34.03M
-11.3% YoY
Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. slides, 8-K earnings release stay in one workspace.
Plasma / NexSys Performance 54
Blood Management Technologies / TEG 51
Guidance Reaffirmation and Long-Range Plan 50
Geographic Mix and International Growth 42
Interventional Technologies Turnaround 37
Portfolio Transition / Whole Blood Divestiture 18
Management tone
Positive
Net tone +38 · moderate hedging
Grounding quotes
- “We are reaffirming full year revenue guidance of a 3% to 6% reported revenue decline, but 6% to 9% organic growth ex CSL.”
- “I am cautiously optimistic, but it will take time to build.”
- “We view recent softness as executional, not structural, and we have taken decisive steps to strengthen our performance.”
- “Strong growth in our base business, margin expansion, and the most recent share buybacks drove 8% adjusted EPS growth to $1.10.”
Forward guidance
7 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 7, 2025.
| Metric |
Period |
Guided |
Basis |
|
Total Company organic ex-CSL revenue growth
table
Fiscal 2026
|
Fiscal 2026 |
6% – 9% |
Non-GAAP
|
|
Plasma organic ex-CSL revenue growth
table
Fiscal 2026
|
Fiscal 2026 |
11% – 14% |
Non-GAAP
|
|
Hospital reported revenue growth
table
Fiscal 2026
|
Fiscal 2026 |
8% – 11% |
GAAP
|
|
Hospital organic revenue growth
table
Fiscal 2026
|
Fiscal 2026 |
8% – 11% |
Non-GAAP
|
|
Adjusted earnings per diluted share
table
Fiscal 2026
|
Fiscal 2026 |
$4.70 – $5.00 |
Non-GAAP
|
|
Adjusted operating margin
table
Fiscal 2026
|
Fiscal 2026 |
26% – 27% |
Non-GAAP
|
|
Free cash flow
table
Fiscal 2026
|
Fiscal 2026 |
$160M – $200M |
Non-GAAP
|
Quarter detail
How the reported period landed and where the business moved.
Revenue · segments
Med Surg$139.66M
Plasma$129.90M
-4.4% YoY
Blood Center$51.84M
-21.7% YoY
